Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Discussing the Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL) landscape and new drug developments

Ticker(s): RHHBY, NVS, TKPYY, MPSYF, MOR.F

Who's the expert?

Name: Dr Fredrick Hagemeister - MD

Institution: UT MD Anderson

  • Internist and Professor of Medicine, Department of Lymphoma/Myeloma at MD Anderson Cancer Center.
  • Sees about 2-3 new patients a week with relapsed/refractory DLBCL and regularly give lectures on the topic. 
  • Main interest has been on the management of Hodgkin and aggressive lymphomas; has participated in multiple clinical trials of management of patients with all types of lymphomas and has served as PI.

Interview Questions
Q1.

Please describe your background and clinical practice. Roughly how many patients with RR LDBCL do you currently manage?

Added By: c_admin
Q2.

How has the treatment paradigms in r/r/ DLBCL changed with respect to CAR-T therapies given the addition of new products.

Added By: c_admin
Q3.

What are your initial thoughts of the data available from MorphoSys' Phase 2 trial assessing the safety and efficacy of lenalidomide combined with MOR208?

Added By: c_admin
Q4.

Do you think the addition of Polatuzumab Vedotin (pola) to Bendamustine and Rituximab (BR) is an effective combination in treating r/r DLBCL?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.